Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
58   Company Presentation Onsite Information   관리자   2019-05-20   36  
57   [KSMO 2019] Invitation Letter_Dr. Jin-San Yoo   관리자   2019-03-27   309  
56   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a lecture at DGIST Brain and Cognitive Sciences   관리자   2019-02-07   464  
55   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the 2nd Korean Immuno-Oncology Symposium 2019 March 8th,   관리자   2019-02-07   600  
54   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to host CEO Roundtable at WuXi Healthcare Forum 2019 March 5-6,   관리자   2019-02-07   496  
53   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to attend to JP Morgan's Korea Conference 2019 (February 21-22).   관리자   2019-02-07   376  
52   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine was invited to attend as MAB working group expert for EDQM MAB Experts meeting   관리자   2019-02-07   226  
51   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine, Dr. Weon Sup Lee, Head of R&D Center, Dr. Sung Woo Kim, Head of BD were invited by JP Morgan Healthcare Confe   관리자   2019-02-07   1,905  
50   Quarterly Magazine KoNECT 14호(2018.12)_Interview of Dr. Jin-San Yoo   관리자   2019-01-14   265  
49   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Weon Sup Lee, Head of R&D center and PharmAbcine R&D staffs have attended and presented their R&D progress of both TTAC-0001 (Tanibirumab) and PMC-309 projects funded by KDDF   관리자   2019-01-14   273